Sammons, Sarah <br/><br/>
Practical Treatment Strategies and Future Directions After Progression While Receiving CDK4/6 Inhibition and Endocrine Therapy in Advanced HR  [electronic resource] 

 -  Clinical breast cancer  02 2020 
 - 1-11 p.  digital 
<br/><br/> Publication Type: Journal Article 
<br/><br/><label>ISSN: </label>1938-0666 
<br/><br/><label>Standard No.: </label>10.1016/j.clbc.2019.06.017  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Antineoplastic Agents, Immunological--pharmacology<br/>Antineoplastic Combined Chemotherapy Protocols--pharmacology<br/>Aromatase Inhibitors--pharmacology<br/>Biomarkers, Tumor--genetics<br/>Biopsy<br/>Breast--pathology<br/>Breast Neoplasms--genetics<br/>Chemotherapy, Adjuvant--methods<br/>Class I Phosphatidylinositol 3-Kinases--genetics<br/>Cyclin-Dependent Kinase 4--antagonists & inhibitors<br/>Cyclin-Dependent Kinase 6--antagonists & inhibitors<br/>Disease Progression<br/>Drug Resistance, Neoplasm--genetics<br/>Female<br/>Humans<br/>Mastectomy<br/>Precision Medicine--methods<br/>Progression-Free Survival<br/>Protein Kinase Inhibitors--pharmacology<br/>Receptor, ErbB-2--metabolism<br/>Receptors, Estrogen--genetics<br/>Receptors, Progesterone--metabolism<br/>Selective Estrogen Receptor Modulators--pharmacology<br/>Sequence Analysis, DNA